Trials https://www.nct-dresden.de/de/trials https://www.nct-dresden.de/@@site-logo/logo-nct.svg Trials Nivolumab-NPC Prelude PRT7732 Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer iHIT-HGG Register TroFuse ELEMENT (GBG 114) EmpowHER-303 PRSZT Register ARCUS PRISM-1 IMCODE003 GO44479 A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC CHONQUER Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen IOV-MEL-301 AMG20210081 Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation Pacellio MOSAIC IDUNN / MC-MSC.1 OptiMATe MYF3001 TELIOS TL-895-201 < 20 frühere Inhalte 1 ... 8 9 10 11 (aktuell) 12 13 Die nächsten 20 Inhalte >
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
IMCODE003 GO44479 A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
CHONQUER Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
AMG20210081 Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
